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A B S T R A C T   
Coronavirus disease-19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
The SARS-CoV-2 virus strains has geographical diversity associated with diverse severity, mortality rate, and 
response to treatment that were characterized using phylogenetic network analysis of SARS-CoV-2 genomes. 
Although, there is no explicit and integrative explanation for these variations, the genetic arrangement, and 
stability of SARS-CoV-2 are basic contributing factors to its virulence and pathogenesis. Hence, understanding 
these features can be used to predict the future transmission dynamics of SARS-CoV-2 infection, drug develop-
ment, and vaccine. In this review, we discuss the most recent findings on the mutations in the SARS-CoV-2, which 
provide valuable information on the genetic diversity of SARS-CoV-2, especially for DNA-based diagnosis, an-
tivirals, and vaccine development for COVID-19.   
1. Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an 
enveloped RNA virus, belongs to the Betacoronavirus genus. This genus 
includes zoonotic RNA viruses that have led to recent important epi-
demics: SARS (Severe Acute Respiratory Syndrome) in 2002 and MERS 
(Middle East respiratory syndrome) in 2012 [1]. Worst of all, in 2019, a 
pandemic by SARS-CoV-2 emerged in Wuhan city with acute pneumonia 
symptoms, which spread fast globally. The rapid dissemination and the 
worldwide outbreak of coronavirus disease 2019 (COVID-19) have 
caused to notify essential questions about the viral population’s adap-
tation and evolution caused by mutations, recombination, and deletions. 
The viral genome mutations related to different agents and factors such 
as viral replication enzymes, host enzymes, recombination events, 
spontaneous nucleic acid damages, and particular genetic elements are 
liable for generating new variants [2]. 
Remarkably, genetic differences in RNA viruses’ genome occurred 
while being mainly distributed by an individual outbreak as a natural 
by-product of viral replication [3]. However, in the case of SARS-CoV-2, 
fewer mutations have been reported than most RNA viruses because 
they possess an enzyme that can correct some errors of replication. As 
the first line of defense against a broad range of pathogens, especially 
viruses, innate immune response, has raised this evolution and adapta-
tion [4]. Viral adaptation brings a balance between genome variability 
and the integrity of genetic information, and the rate of mutation in RNA 
virus contributes to this adaptation [5,6]. Several reports have demon-
strated that the deletions in the viral genome of SARS-CoV-2; often 
generate deletion variants of accessory and non-structural proteins, 
which probably directly affect viral virulence [7–9]. Upon genomic 
analysis, SARS-CoV-2 has various variants categorized into three types 
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A, B, and C. Although these SARS-CoV-2 types possess different gene 
mutations, these mutations’ effect is debat [10]. Moreover, geographical 
propagations may lead to different genetic strains of SARS-CoV-2 from 
various locations [11]. 
In this review, we aim to discuss the most recent findings on the 
mutations in the SARS-CoV-2, which may be valuable information for 
the genetic diversity and genetic etiologies in the virus and, and for 
diagnostic and therapeutic strategies of SARS-CoV-2 especially for DNA- 
based diagnostic, drug design and vaccine development against COVID- 
19. 
2. Evolution of viruses and mechanisms of viral mutation 
Genetic diversity depends on various parameters. Among these, the 
mutation rate is of great importance because of its special place as a 
source of genetic variation [2,12]. In fact, mutations are the building 
blocks of most evolutions [12]. Mutation rates among viruses are very 
high. Most differences are present between DNA and RNA viruses 
(Table 1). RNA viruses mutate more quickly than DNA viruses. Studies 
showed that mutation rate ranges between 10 and 8− 10− 6 for DNA 
viruses and 10–6–10− 4 for RNA viruses [13]. Eventually, for an un-
known reason, single-stranded viruses tend to mutate faster than 
double-stranded ones; resulting in that mutation rates of single-stranded 
DNA viruses be incomparable with double-stranded RNA viruses [13]. It 
seems that there are no differences between single- or double-stranded 
RNA viruses. One possible explanation for this event is that 
single-stranded genomes are more sensitive to oxidative deamination 
and other kinds of chemical damage. Differences among single- or 
double-stranded RNA viruses may be due to their access to 
post-replicative repair [2]. 
Genome size seems to have a negative correlation with mutation 
rate. The high mutation rate of RNA viruses is related to the short length 
of the genome. Some DNA viruses with larger genome sizes code a DNA 
repair protein. RNA-dependent RNA polymerase (RdRp) is the other 
parameter for a higher mutation rate of RNA viruses. Unlike many 
polymerases involved in the replication of DNA viruses, RdRp does not 
have a proofreading activity. This enzyme is incapable of correcting 
mistakes occurring during viral replication because it lacks a 3′ exonu-
clease domain. Retroviruses reverse transcriptase (RT) enzyme has the 
same property that permits them to mutate and evolve very fast [2]. 
Unlike most RNA viruses, the order of Nidovirals including, Roniviruses, 
Toroviruses, and Coronaviruses, have an RdRp independent proof-
reading activity. They encode RdRp containing a 3′ exonuclease region 
and thus show lower mutation rates. This feature seems to be a critical 
factor in describing how these viruses possess larger genomes (26 kb) in 
comparison with other RNA viruses. 
It should be noted that besides viral factors affecting the mutation 
rate of the virus, host encoded factors such as Double-strand RNA- 
dependent adenosine deaminases (ADARs), Apolipoprotein B mRNA 
editing catalytic polypeptide-like enzymes (APOBEC), and uracil DNA 
glycosylases (UNG) influence deeply on viral mutation rate [12]. 
Finally, the viral mutation rate is determined by multiple viral and 
host mechanisms including proofreading activity, environmental 
changes, genome size, polymerase fidelity, replication mechanisms, post 
replicative repair, sequence background, template secondary structure, 
spontaneous nucleic acid damage, editing by host-encoded deaminases, 
imbalances in nucleotide pools [2]. 
3. Genetic material of SARS-CoV-2 
Wu et al. reported the first genomic sequence of SARS-CoV-2 from a 
worker of the Wuhan market on 26 December 2019 [46]. The accession 
number of this sequence in the National Center for Biotechnology In-
formation (NCBI) GenBank [47] has been provided since January 2020 
(NC_045512). The arrangement of this positive single-stranded RNA 
genome sequence is 5́-untranslated regions (UTR)- non-structural region 
(replicase complex[ORF1ab])-structural region (Spike-Envelope-Mem-
brane-Nucleocapsid proteins)− 3́ UTR (Fig. 1). The non-structural region 
consists of replicase polyproteins, which are essential for replicating and 
transcribing the viral genome. Sixteen non-structural genes in this re-
gion nsp1–16 [48] encode proteins needed for the virus’s biochemical 
and molecular functions in host cells. Nsp1 or host shutoff factor, which 
suppresses innate immune in the host, binds to the human ribosomal 
complexes in the 40 S subunit, consisting of the 43 S pre-initiation 
Table 1 
The viral mutation rate in human infecting viruses.  
Class Virus Genome size (kb) Average mutation rate References 
ss (+) RNA Human Rhinovirus 14  7.13 6.9 × 10− 5 [14,15]  
Poliovirus 1  7.44 9.0 × 10− 5 [16–18]  
Coxsackie B virus  7.4 4.76 × 10− 3 [19]  
Human Norovirus G1  7.65 1.5 × 10− 4 [20]  
Hepatitis C virus  9.65 3.8 × 10− 5 [21,22]  
Zika virus  10 6.76 × 10− 4 [23]  
Dengue virus  10.7 7.17 × 10− 4 [24]  
Human_coronavirus_229E  27.3 3.28 × 10− 4 [25,26]  
SARS_coronavirus  29.7 2.80 × 10− 3 [27] 
ss (-) RNA Vesicular stomatitis virus  11.2 3.7 × 10− 5 [24,28]  
Rabies virus  11.9 3.97 × 10− 4 [29]  
Influenza A virus  13.6 2.5 × 10− 5 [30,31]  
Human Parapneumo virus  13.34 7.12 × 10− 4 [32]  
Mumps Virus  15.38 9.17 × 10− 4 [33]  
Measles virus  15.9 3.5 × 10− 5 [34]  
Respiratory Syncytial Virus  15.19 2.31 × 10− 3 [35]  
CCHFV  19.15 9.87 × 10− 5 [36] 
ds RNA Human rotavirus A  18.56 1.76 × 10− 3 [37] 
Retro (Reverse transcribing) Human Hepatitis B Virus  3.22  3.21 × 10− 4 [38]  
Human T Cell Leukemia virus  8.50 1.6 × 10− 5 [39]  
HIV-1  9.18 6.3 × 10− 5 [40,41]  
Rous sarcoma virus  9.40 1.4 × 10− 4 [38] 
ss DNA Human Parvovirus_B19  5.59 1.55 × 10− 4 [42] 
ds DNA JC Polyomavirus  5.13 1.7 × 10− 5 [43]  
Human Adenovirus 5  35.9 1.31 × 10− 7 [2]  
Herpes simplex virus type1  152 5.9 × 10− 8 [44]  
Human cytomegalovirus  235 2.0 × 10− 7 [45]  
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complex and the non-translating 80S ribosome [49]. Nsp2 and S protein 
have shown a significant stimulatory effect on the type-I interferon (IFN) 
induction [50]. Two proteases are encoded in the SARS-CoV-2 genome. 
One of them is a papain-like protease (PLpro) encoded in nsp3, which 
cleaves nsp1, nsp2, and nsp3. The other one is 3–chymotrypsin-like 
“main” protease(3CLpro) encoded in nsp5, which processes 13 other 
non-structural proteins after production [51]. It is indicated that nsp7 
and nsp13 are related to T-cell immune response [52]. Nsps 12–16, 
encoding RNA-dependent RNA polymerase (RdRp), helicase, 
3′-to-5′exonuclease; endoRNAse and 2′-O-ribose methyltransferase, 
respectively are linked with virus replication and transcription. 
The structural region is another part of the SARS-CoV-2 genome that 
encodes four major structural proteins (Spike (S), Membrane (M), En-
velope (E), and Nucelocapside (N)). S protein binds to receptor (angio-
tensin-converting enzyme 2 (ACE2)) and fuses to the host cell membrane 
[53]. After S, ORF3a is located in the SARS-CoV-2 genome, which en-
codes an essential accessory protein. This protein can induce apoptosis, 
but the pro-apoptotic activity of ORF3a in SARS-CoV-2 is relatively 
weaker than SARS-CoV ORF3. It is probably associated with mild 
symptoms or asymptomatic during the early stages, which leads to 
spread more widely for this virus[54]. 
The E protein is the most mysterious structural protein among the 
four once, which plays a crucial role in the ER-Golgi localization and 
tight junction disruption[55]. M protein is the most abundant structural 
protein in coronaviruses that span virion membrane and along E protein 
have an important role in virus assembling. ORF6, ORF8, and nucleo-
capsid (N) proteins are other structural proteins that are inhibitors of the 
interferon type 1 signaling pathway. This interferon is a critical factor in 
the host’s innate immune for the antiviral response[56,57]. 
4. Types of variation in SARS-CoV-2 
Since the inception of the COVID-19 pandemic, exploration of SARS- 
CoV-2 genetic variation has been a notable subject globally, promoting 
the development of vaccines and diagnostics [58]. Several studies using 
various genomic sequences have performed the phylogenic analysis of 
SARS-CoV-2 around the world [58–61]. Koyama et al. analyzed 10022 
SARS CoV-2 genomes from 68 countries. They detected 5775 distinct 
variants include two in-frame insertions, 11 frame-shift deletions, 36 
stop-gained variants, 66 non-coding insertions, 100 in-frame deletions, 
142 non-coding deletions, 484 non-coding regions mutations, 1965 
synonymous mutations, and 2969 missense mutations. They finally 
reported six major clades consisting of basal, D614G (the largest clade), 
L84S, L3606F, D448 deletion, and G392D, also 14 subclades [60]. 
A comprehensive study analyzed 12343 SARS-CoV-2 genome se-
quences isolated from around the world. Also, an investigation was 
performed on variants’ correlation with the fatality rates in several 
countries. By 16 common amino acid mutations in hierarchical clus-
tering, 28 countries were classified into three clusters [62]. Cluster 1 
was China, Korea, Japan, India, and Singapore. Cluster 2 includes En-
gland, Iceland, Netherlands, Greece, Portugal, Brazil, Italy, Switzerland, 
Belgium, Hungary, and cluster 3 contains the USA, Taiwan, Australia, 
Canada, Thailand, Spain, Denmark, Congo, Germany, Sweden, Finland, 
France, and Luxemburg. Final analyses of variant frequency showed that 
the frequency of ORF1ab P4715L, S 614 G, and N 203 K/204 R variants 
was higher in cluster 2. The frequency of N 13 L and ORF1ab 3606 F was 
higher in cluster 1. According to the reported S protein 614 G variant 
data and ORF1ab 4715 L, as its highly linked variant, it was consider-
ably associated with fatality rates in all 28 countries also 17 states from 
the United States [59]. 
In a recent study, Yellapu et al. analyzed 540 SARS-CoV-2 genomes 
from 20 different countries. They reported five distinct clusters. Ac-
cording to their results, 246 genomes among all 540 genomes indicated 
amino acid variation in one of the four structural genes. A high rate of 
amino acid variation was seen in spike protein. They reported that 202 
genomes indicated 34 types of changes in amino acid consist of D1259H, 
N1178D, D1168H, A1078V, S940F, D936Y, A930V, F797C, Q675H, 
H655Y, D614G, A570V, A520S, H519Q, V483A, G476S, R408I, A348T, 
A344S, S248R, T240I, S221W, G181V, F157L, D111N, E96D, N74K, 
L54F, S50L, H49Y, T29I, Y28N, A27V, L5F. The D614G mutation was 
reported as the most frequent variation (in 160 genomes). Also, they 
reported 25 types of variation in N structural protein among 65 genomes 
include P344S, D343V, S327L, Q289H, T271I, G238C, S232T, G215S, 
A207G, T205I, G204R, R203K, S202N, S197L, S194L, R185C, D128Y, 
P46S, A35T, S23T, P14L, P13L, P6T, N4D, D3Y. In this group, R203K 
was reported as the most frequent (in 21 genomes). For protein M, A2S, 
V70I, T175M were reported in 6 genomes, and EL37R and P71L were 
reported just in 3 genomes[63]. 
According to another study, the D614G variant was reported as a 
high frequent mutation in different European countries, also Turkey and 
Iran [64–67]. Studies have shown that D614G in S protein is dominant in 
pandemic and also is related to more infectivity, transmission, and 
higher viral load[68]. Some studies exhibit that patients infected with 
the spike 614 G variant show higher mortality or clinical severity, but 
Fig. 1. Schematic structure of SARS-CoV-2 genome.  
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614 G is associated with higher viral load especially in younger patients 
[69]. Other studies show that this mutation results in an open confor-
mation of the spike receptor-binding domain (RBD), and increase 
binding affinity to ACE2 and fusion to the host cell, which in turn leads 
to an increase in SARS-CoV-2 transmissibility and infectivity. Moreover, 
lower ACE2 expression that is reported in European populations, North 
American, and African than that of Asian populations is associated with 
enhanced transmission efficiency. This indicates a positive selection for 
the D614G mutation[70]. However, this mutation is fortunately located 
outside of the RBD, so it probably does not affect vaccine design in the 
currently viral lineage[67]. Some mutations in the receptor binding 
domain such as V367F and D364Y seem that can improve the stability of 
the spike protein structure and lead to more efficient binding to the ACE 
receptor[71]. Another mutation in spike protein, V483A, to be notice-
ably resistant to monoclonal antibodies[63]. On 14 December 2020, a 
new variant of SARS-CoV-2 was reported from the United Kingdom and 
named SARS-CoV-2 VOC 202012/01. This variant is consisting of 23 
nucleotide substitutions. There is no detected phylogenetically relation 
between this variant and the SARS-CoV-2 virus flowing in the U. K[72]. 
This "English variant" is including multiple mutations in spike protein 
(deletion 69–70, deletion 144, substitutions S982A, T716I, P681H, 
D614G, A570D, N501Y, and also D1118H) in addition to the other 
genomic regions mutations[73]. Among spike mutations, N501Y is one 
of the six important residues responsible for the interaction of RBD with 
ACE2, so this is a major worry and has been related to enlarged infec-
tivity and virulence in mouse models[74,75]. In addition, the E484K 
mutation in spike protein is an important mutation in the English variant 
and linked with the escape from the neutralizing antibodies against 
SARS-CoV-2[76]. Another variant of SARS-CoV-2 named 20 H/501Y.V2 
emerged in South Africa which was independent of the English variant. 
Three particular spike protein mutations in this variant are N501Y, 
E484K, and K417N. These three mutations were also detected in another 
new variant in Brazil (named 501Y.V3)[77]. Other spike mutations with 
less concern in South Africa variant are A701V, R246I, D215G, D80A, 
and L18F [78]. The other detected mutations in this variant are K1655N, 
P71L, T205I, and SGF 3675–3677 deletion[79]. 
Besides mutation in structural proteins, the mutation in RdRp which 
is responsible for replication (such as P4715L) can be effective for virus 
proliferation [60]. On the other hand, the virus mutagenic capability is 
related to the fidelity of RdRp, which shows the significance of mutation 
in RdRp[1]. 
5. Variant analysis of SARS-CoV-2 genome 
RNA viruses such as SARS-CoV-2 usually show a high mutation rate 
that may be due to the deficiency of proofreading abilities generally by 
an RNA-dependent RNA polymerase (RdRp) [80]. There are several 
studies on the variant analysis of the SARS-CoV-2 genome worldwide, 
within the year of the virus pandemic. For the whole genome of 
SARS-CoV-2 with 29,870 nucleotides and 9744 amino acid residues, 
large amounts of mutations were reported from December 2019 until 
now in 5′ and 3′ UTR, intergenic regions, and the coding sequences [81]. 
In a large analysis of variants on 48,635 SARS-CoV-2 genomes, a 
total of 353,341 mutation events were recorded [82]. Another fact in the 
mentioned project is that although 256 samples, mostly from Asia, did 
not have any variation in comparison to the NC_045512.2 Wuhan 
reference genome, 48,379 genome samples were specified with at least 
one mutation. The number of mutations is relatively low, 7.23 on 
average per sample. However, few samples harboring more than 15 
mutations in the whole genome [82]. 
Overall, for 5′ and 3′ UTRs, it was reported that mutations occur in 
high frequency. For example, in the study of Rouchka, et al., surveyed 
1043 filtered sequences, about 229 and 152 mutations were reported for 
5′ and 3′ UTRs, respectively [83]. These statics from another study 
conducted by Rafiul Islam investigated a total of 2492 genome se-
quences and generally reported 1516 nucleotide‑level variations, is 105 
and 158 cases, respectively [84]. The final study, in this case, was a 
variant analysis of 10,022 genomes and representation of 260, and 224 
variants for two parts of the genome from the total 65,776 variants [60]. 
However, because these parts of the virus genome are non-coding se-
quences, their final impact was not properly understood. But it was clear 
that 29742G > T, in the 3′ UTR stem-loop II-like motif (s2m), is 
important in involving host transcriptional machinery and virus repli-
cation[84]. The mentioned mutation was detected in >1% within 
SARS-CoV-2 isolates. Furthermore, two deletion mutations were detec-
ted in the 3′ UTR from a total of 2492 surveyed sequences [84]. 
Although the mutations of the SARS-CoV-2 genome are very com-
mon, there are some variants with higher frequency. For example, Wang 
et al. [85], identified ten high-frequency mutations within 108 genome 
isolates and used them to classify SARSCoV-2 into five main groups. In 
the other study conducted by Yang, 14 prevalent mutations with a 
mutation frequency of > 0.1 were identified [82] which will be dis-
cussed later. 
The mutations in the coding sequences of SARS-CoV-2 were more 
investigated because of their effects on the structure or function of the 
protein and the higher length of the protein-coding sequence in the 
genome. Some of the variations in the studied genome are very routine, 
led to classify the genome sequence as clades. In one study, totally, 
10,022 SARS-Cov-2 genomes were analyzed and it was shown that 
exactly 65,776 variants occurred in the surveyed genomes which 2969, 
and 1965 of them were missense and synonymous mutations, respec-
tively [60]. Due to the longer size of the ORF1ab, 1905 missense variants 
(about 64%) were found in it. Again, in the ORF1ab, NSP3, was more 
studied for its variants and it was revealed that the two most frequent 
variants were the synonymous variant 3037 C > T (6334 samples), and 
A58T (2891 G > A, in the level genome) missense variant with 159 
samples. On the other hand, in ORF1ab, the 14408 C > T (P4715L) 
variant of the RdRp gene in 6319 samples was the other most prevalent 
missense mutation. For the S protein, the most common missense mu-
tation was 23403A > G (D614G) with 6294 total samples (68 countries) 
and assumed as the most common point mutation with 36,500 positive 
cases from a total of 48,635 samples [82]. 
In ORF3a, 25563 G > T (Q57H in the proteome level) with 2893 
samples (from total 10,022 full-length genome), was the most prevalent 
missense variant. Finally, for ORF1ab, NSP2, 2442 positive samples for 
1059C > T (T265I) was detected. Most samples containing 23403 A 
> G, also display the non-coding variant 241C > T, the synonymous 
variant 3037C > T and ORF1ab P4715L [60] (Table 2). 
5.1. Classification of routine missense variants in clades 
Based on the most occurred missense mutations, the variants were 
classified into some clades. Koyama, et al., provided a division of total 
clades with several sub-clades, for the first time. The first clade named 
Basal clade originated from China in Dec 2019, and the number of cases 
belonging to this clade is gradually decreasing. D614G (also called G 
clade), was the name of the second clade in which all genomes contain a 
missense mutation in the S protein, 23403A > G. The amino acid in this 
position of S protein, play an important role in the entrance of SARS- 
CoV-2 into the host cell via the ACE2 human receptor[60]. It was 
established that three other missense mutations including 14408 C > T, 
241 C > T, and 3037 C > T, show a similar frequency with 23403A > G 
and almost always co-occurring in the same genomes and are belonging 
to the G clade. Within the D614G clade, D614G/Q57H/T265I subclade 
(also named as GH clade) forms the largest subclade with 2391 from 10, 
022 samples [60]. 
The third-largest clade was L84S clade (S clade), with a missense 
mutation in ORF8 (28144T > C) and with the most similarity to the 
basal clade. This variant originated from the travelers of Wuhan. L3606F 
was the other presented clade with a mutation in the NSP6 of ORF1ab in 
approximately 1070 samples and had the most frequency in China [60]. 
One of the introduced clades contains a deletion mutation in the 
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NSP2 gene as an in-frame deletion led to exclude an Aspartic acid in the 
NSP2 protein and named as D448del. The prevalence of this clade 
worldwide was about 2.5%, worldwide [60]. 
G392D was the last clade with the least number of samples contains a 
mutation in the position of 1440 G > A of the NSP2 gene which has 
shown more abundance in Germany [60]. 
5.2. Transition versus transversion mutations 
Generally, the most common nucleotide change in the SARS-CoV-2 
genome, is C > T (as a transition mutation), accounting for 55.1% of 
all observed viral mutations, worldwide [82]. Surprisingly, for muta-
tions that occurred in the SARS-CoV-2 genome, the transition versus 
transversion ratio was calculated as about 7:3. C > T transitions might 
be mediated by cytosine deaminases [60]. After that, the A > G espe-
cially in Africa, Europe, and the Americans has shown a rate of 14.8%. 
The third most common event worldwide, G > T, which is the most 
common transversion showed a rate of 12.0% (42,408 occurrences) may 
occur as a result of an oxo-guanine lesion from reactive oxygen species 
[82]. 
5.3. Very common mutations in the SARS-CoV-2 genome 
As a summary for the most prevalent variants of the SARS-CoV-2 
genome, it can be said that 28144T > C, in the ORF8, lead to a 
missense mutation as L84S, was recognized as a common mutation in 
the virus genome [61]. This mutation was reported in another study 
with frequency as 1669 samples from a total of 10,022 genome se-
quences [60]. In Khailany, et al. study, this variant assumed as the 
second prevalent mutation after the 8762 C > T [86]. This mutation was 
founded on 5th Jan 2010 for the first time co-observed with 8782 C > T, 
and the variants with two these mutations called as S type (S clade) in 
comparison to the native L clade of the genome [87], leads to improve 
the replication fidelity in this RNA virus. However, the frequency of two 
of these mutations has gradually declined over time [87]. 
The transition mutation of 8782 C > T, in the NSP4 gene, on the 
other hand, co-appeared with 28144T > C, was assumed as the earlier 
mutation with decreasing frequency over time[87]. Newer mutations 
such as 14408 C > T, especially in Europe, lead to a missense mutation 
in the RdRp gene as P323L, was occurred with a higher frequency for 
6319 samples [60]. This mutation is the characteristic of G clade and 
resulted in higher transmissibility of the virus [87]. 
The variants containing 23403A > G mutation with an amino acid 
substitution from aspartic acid to glycine in the S protein, are the other 
most prevalent variants especially in European samples that created a 
more transmissible form of SARS-CoV-2 [11]. This mutation is one of the 
four prevalent mutations co-occurred in the G clade similarly to the 
3037 C > T as a synonymous mutation showed the highest prevalence as 
above 6300 from over 10,000 samples and was very routine in the 
Russian samples too [60,88]. 
Guanidine substitution with Thymidine or Cytidine in the 11083th 
nucleotide of NSP6 gene was not related to the other frequent mutations 
and especially related to the European samples [10]. However, in the 
Koyama study, it was shown that this missense mutation occurred with 
frequency as about 1100 samples [60]. 
The other more common point mutation was 26144G > T, in ORF3a 
resulted in G251V in the proteome level and was more prevalent in 
European surveyed samples [87]. This type of mutation was assumed as 
the third prevalent variant after the 8782 C > T and 28144T > C, as a 
single mutation according to the Yin et al. study [80]. 
Finally, in one study, a single point mutation has been shown as 
21707T > C, corresponds to H49Y amino acid substitution in the S 
protein, and occurred with a frequency of 0.4% from a total of 4533 
surveyed sequences, until 6 May 2020. The first date for creating this 
variant was estimated as 12 Jan 2020 and emerged again in all the se-
quences obtained from Mexico. Since then, this mutation has appeared 
as a singleton in various virus variants worldwide [13]. However, the 
final effect of this variant has not yet been fully studied [89]. 
6. Geographic distribution of SARS-CoV-2 mutations 
Given that the SARS-CoV-2 originated from China, it can be said that 
the studied samples from Asia show the least difference compared to the 
reference genome. However, over time, the average mutation counts per 
sample increased around the word. This situation can be a sign that the 
mutant strains are persistent and further spread [87]. From the total 48, 
635 sequences, in the study of Mercatelli et al., 48,379 samples 
possessed at least one mutation [82]. On the other hand, it was found 
that there is no significant difference between continents in the average 
rate of mutations, but there is a significant difference in the average 
number of mutations per sample between countries. Actually, among the 
top 40 countries with the most number of full-length viral genomes, 
India, Congo, Bangladesh, and Kazakhstan indicated mutations per 
sample equal to 8.40, 8.30, 9.83, and 9.47, respectively that were the 
highest values of observed mutations per sample, in comparison to the 
world average as 7.23 [82]. On the contrary, the number of mutation per 
sample for sequences originated from European countries such as Ger-
many, Italy, and Greece was calculated as about 5.97, in average, and 
this value for Japan was reported as 4.55, which was significantly lower 
than the world’s average [82]. These statics for the US, in another study, 
was about 6.42 with the worldwide average reported as 5.654 [87]. 
However, in an earlier study, performed in the time interval of Dec 
Table 2 









Final impact Reference 
241C > T 5′ UTR – – Important in transcription and viral packaging [17] [1,6] 
1059C> T Missense NSP2 T265I Increasing the protein stability [18] [6,10,19] 
2891G > A Missense ORF1ab/ 
NSP3 
A58T important role in viral replication [20] [6,21] 
3037C > T Synonymous ORF1ab/ 
NSP3 
F106F/F924F no obvious effects on critical interaction to Nucleocapsid protein [22] [1,3,6] 
8782C > T Synonymous NSP4 S2839S No obvious effects in infection ability and transmissibility [6,3,10, 
23] 
14,408C > T Missense ORF1ab/ 
RdRp 
P4715L/P323L altered interaction with other components of the replication/transcription machinery or 
with the RNA template [24] 
[1, 3, 6, 10] 
23403A > G Missense S D614G increased transmissibility for viruses [25] [1,2,3,6] 
25563G > T Missense ORF3a Q57H the binding affinity of Q57H Orf3a–S complex showed the greatest increase with S protein 
[26] 
[6,10,15] 
29742G > T 3′ UTR – – viral replication and recruitment of host transcriptional machinery [5] [5] 
28813G > T Missense S K417N enhancement of the binding of RBD to ACE2 (L) [94,95] 
23012G > A Missense S E484K improve escape from immune system antibodies (I) [76,96] 
23063A > T Missense S N501Y Viral infectivity and virulence (C,D) [74,76]  
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2019-Mar 2020; among a total of 1932 SARS-CoV-2 studied strains, the 
average mutation counts per sample in American and European pop-
ulations were much higher than that in Asia populations. Spain, 
Belgium, and Finland in Europe showed the highest average mutations 
per sample while Singapore, Japan, and China were on the opposite side 
[87]. These different results are probably due to the inclusion of the 
genome information related to China with the lower mutation count to 
the Asian samples. Actually, because most of the recorded genome se-
quences in the early months of the outbreak were related to China, this 
nation showed a lower mutation per sample. Nonetheless, a small 
number of sequences carrying more than fifty mutations are associated 
with China, shifting this average rate [90]. 
As a conclusion of this section, it should be said that according to the 
investigated samples until Apr 9, 2020, it was shown that there was a 
strong linear correlation between the number of average mutations per 
sample and the case fatality rate. Another reported result is the fact that 
the mutations in ORF1ab, with a significant number of mutations, may 
contribute the most to the case fatality rate [87]. 
For comparing the frequency of various clades between different 
countries, it may be said that in the study of Koyama, it was reported 
that G clade, was most prevalent in China, while the results of Mercatelli 
et al. study showed that South America, Europe, Africa, and Oceania had 
the most frequency of the D614G clade. One reason for this difference is 
the fact that Mercatelli’s study covered the genome sequences until Jun 
2020, while the Koyama study is older and the collected samples were 
from Dec 2019–1 st of May 2020 which most of the samples originated 
from China, and virus distribution was at this time [90]. 
The study of Mercatelli showed that the G and GR clades are prev-
alently present in Europe, while the clade S (L384S mutant) have been 
mostly seen in the Americas. The L clade, as the reference (basal clade), 
is mostly represented in Asia samples (predominantly related to China 
genome sequence). This clade is composed of about 7% of the sequenced 
genomes until the last day of Mar 2020, and as expected, the G is the 
most common clade around the world, especially, in North America and 
Europe. More precisely, North America, especially the US, was reported 
with the most positive cases of D614G and Q57H, as GH subclade. In 
South America and Europe, the most frequent clade was GR (containing 
D614G and RG203KR mutations). For Oceania, on the other hand, there 
is a balance between all introduced clades. For Africa and Asia, G ge-
nomes were with more frequency than other clades. In Europe, Denmark 
and France, for example, showed the higher presence of GH while the 
United Kingdom and Portugal show higher numbers of GR. Finally, 
Russia and Brazil belong to clade GR. Overall, the incidence of G clade is 
increasing over time, worldwide [90]. 
G251V, a point mutation as 26144G > T, is a clade first created in 
Feb 2020. This variant frequently appeared in samples from the United 
Kingdom, Iceland, the United States, and Australia [60]. 
As another geographical analysis study in the case of SARS-CoV-2, 
we can refer to the study of Taboada, et al., surveyed the samples 
separated from Mexican patients with the Covid-19 positive test. The 
results of this study showed that all Mexican sequences have 241C > T 
and 23403A > G, related to G clade [91]. 
In the Middle East countries, however, there are a few investigations 
about SARS-CoV-2 mutations. The results of a study that investigated 
only eleven full-length genome sequences from Lebanon until Mar 2020, 
showed that the most prevalent variants were 23403A > G (D614G), 
clade G, and the second common mutant was 14408C > T, in ORF1ab, 
resulted in a missense mutation as P4715L, one of the three mutations 
mostly co-occurred with 23403A > G harboring genome. The pattern of 
variations in this study was equal to the European countries, at the same 
time which is rational according to their short distances [92]. 
Another study, for some countries especially from Asia, with data 
analysis of 2200 full-length genome sequences until Jun 2020. The re-
sults of this study established that 241 C > T, 3037 C > T related to the 
G clade, and 14408 C > T, co-occurred with the mutations in G clade, 
and also 11083G > T, most prevalent in Europe samples, was the most 
prevalent mutations. The other report is this fact that the Iranian sam-
ples showed more diversity and interestingly did not reveal 14408C > T 
mutation, common in most samples. Furthermore, samples from Iran, 
appeared lower average point mutation frequency than other countries, 
related to earlier virus epidemics in comparison to the other investigated 
countries [93]. For other nations, similar variant mapping was showed. 
However, in the case of Qatar, frame-shift mutations occurred with a 
higher frequency [93]. 
The mutations including 3037 C > T, 14408 C > T, 23403A > G, and 
241 C > T were more common in Europe and hardly observed in other 
countries. The American countries, on the other hands, was showed that 
contain mutations 8782 C > T and 28144T > C. Additionally, the 
Americas also carried mutations 17747C > T, 17858A > G, and 18060C 
> T, which all of them showed a frequency more than 0.1% according to 
the Koyama’s study [60,68]. 
Due to the importance of spike protein in pathogenicity and immu-
nogenicity, we retrieved all Spike sequences submitted to NCBI (until 
10th January 2021) for each continent and after deletion of the repeated 
sequences and multiple alignments, Shannon’s entropy plot for each 
continent was attained by using of BioEdit software (Fig. 2). 
7. Conclusion and future perspectives 
Natural selection is a major factor in determining the fate of new 
mutations. The mutations that give a competitive advantage increase. 
These usually involve the virus escaping from the host’s immunity, virus 
replication, and transmission. Also, those mutations that reduce viral 
fitness generally tend to eliminate. On the other hand, mutations can 
occur by chance. Natural selection and chance lead to the evolution of 
the virus into the hosts. 
Whether a mutation changes immune, evasion infectivity, or path-
ogenicity or some combination of these is yet to be implicit. In some 
cases, the mutation may transmit with other mutations simultaneously, 
for example, the mutations that affect the RNA-dependent RNA poly-
merase, with implications on replication efficiency, proofreading, and 
the emergence of resistant phenotypes [1]. Finding the answer to these 
questions depends on worldwide studies to provide comprehensive data 
on infection and mortality rates as well as the continuous sampling of 
the genotypes of circulating isolates all around the world. So far, we lack 
these integrated data and not able to correlate molecular findings with 
clinical and population-level consequences. 
Mutations in the SARS-CoV-2 could have significant effects on the 
severity of the Covid-19 disease, the contagion, and the virus’s stability. 
It is also responsible for re-infection, vaccination strategy failure, and 
convalescence plasma and monoclonal antibody (mAb) therapy due to 
immune-escapes from neutralizing antibody and T cells. It also reduces 
the quality of diagnostic kits and increases the false negative. Another 
point in this regard is the emergence of drug-resistant strains. 
Some of the important mutations in spike glycoprotein that over-
shadow the success of vaccines, plasma therapy, and diagnostic kits 
include L18F, A222V, D614G and Q780E variants in conformational 
epitopes [97], RBD variants of F338L، S373P and R408T [98,99], S477N 
and E484A/K mutations [100], two variant amino acids G446V and 
F456L in a linear epitope [101], and also resistance substitutions at 
R346, N440, K444, G446, N450, L452, S477, T478, P479, E484, F486, 
F490, Q493 and P499 [100–103]. 
By considering the mutation profiles in different parts of the world, 
and the previous debates about the choice of the vaccine strain, using a 
single strain for the vaccine can immunize people be to some extent 
against all strains of SARS-CoV-2. However, in order to achieve 
maximum vaccine coverage and protection in the human, and also high 
immune response and neutralizing antibodies (to prevent immuno- 
escape mutants), a vaccine may be prepared in bivalent, trivalent or 
tetravalent forms. It means it contains a combination of two or three 
different serotypes. At least one of the serotypes must have a D614G 
mutation and associated mutations that alter the interaction of 
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neutralizing antibodies. These mutations change immunogenicity and 
the structure and sequence of immunodominant linear and conforma-
tional epitopes and escape capability from humoral immune pressure, 
otherwise retain the strong binding affinity toward ACE2 [104,105]. 
These points are critically crucial for recombinant vaccines such as; 
mRNAs, DNA, subunits, and viral vector-based vaccines that mostly use 
only full length S protein or truncated S1 subunit in engineering vaccine 
constructs. A shift from monovalent to bivalent or trivalent was previ-
ously used in the Coronaviridae family members for decades and shows 
near 100% protection [106,107]. Also, in the killed (inactivated) vac-
cine, which mainly stimulates the humoral immune system and antibody 
production, it is necessary to pay attention to these points. 
Moreover, due to the high frequency of 14408 (P323L) mutation in 
RdRp, which increases the possibility of mutations and changes in the 
entire virus genome (especially in S protein), it is worthwhile to have at 
least one strain with this mutation in live attenuated and killed vaccine 
mixture. This strategy enriches the pool and stores the antigen of the 
vaccine seeds during passages before formulation. 
Studies have also shown that in recombinant coronaviruses vaccines, 
multivalent vaccines for example those containing proteins S, N, and M 
are more effective than monovalent vaccines that have only S protein 
[108–110]. In this regard, immunoinformatics and antibody-antigens 
simulations with wide abilities and areas could accelerate selecting 
vaccinial strains to incorporate with laboratory tests [106,111]. 
Furthermore, due to mutations in the cleavage region between S1 and 
S2, it is better to consider this region in designing recombinant S1 based 
vaccines that use only S1 length in their construct. 
Besides considering the immunologic effects of mutations, the se-
lection of vaccine strains could also assist according to GISAID nomen-
clature system (https://www.gisaid.org/). In the GISAID database, 
sequenced SARS-CoV-2 genomes were clustered into one of 6 main 
clades includes G, GH, GR, L, S, and V. 
Similarly, most of the points mentioned above are useful for plasma- 
therapy and therapeutic mAbs. It is due to mutations in the virus at the 
sites that cause the neutralizing antibodies to fail to inhibit the virus. It 
decreases the affinity of antibodies to spike glycoproteins [100]. So, it 
could also recommend that the recovered plasma from individuals must 
be pooled and then used to reduce the risk of plasma therapy failure (not 
person to person). Also, in preparing the horse serum for sero-therapy, at 
least three strains or more should be used for immunization to achieve 
more strong neutralizing serum, which improves the rate of success of 
serum therapy. 
Using different drugs will cause drug resistance due to mutations. For 
instance, mutations F480L, V557L, and D484Y in RdRp protein may lead 
to resistance to Remdesivir [112,113]. Therefore, in the treatment, it 
may need to use two to three different drugs (combination therapy) 
against different protein targets to prevent this phenomenon [114,115]. 
Fig. 2. Entropy plots of all submitted Spike protein sequences. The X-axis shows the positions of amino acids and the Y-axis shows entropy scores for individual 
positions in Spike protein. (A) Asia, (B) Europe, (C) Africa, (D) South America, (E) North America, and (F) Oceania. Entropy (Hx) values varied from 0 (high 
conservation) to 1.0 (hypervariable). The amino acids with entropy values less than 0.1 were considered as conserved. 
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C. Ferreira, T.S. Frauches, C.M.B. de Mello, I.C. Leitão, R.M. Galliez, D.S. Faffe, T. 
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